Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Eias Zahalka
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
Oncologist
Cancer Research
Medicine
Oncology
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis
Clinical Cancer Research
Cancer Research
Oncology
Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date
Cancer Management and Research
Oncology
Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Molecular Cancer Therapeutics
Cancer Research
Oncology
Nivolumab in the Treatment of Advanced Renal Cell Carcinoma
Oncology in Clinical Practice
Oncology
Transparency and Dermatologic Device Approval by the US Food and Drug Administration
JAMA Dermatology
Dermatology
Medicine
U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma With Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
Clinical Cancer Research
Cancer Research
Oncology
Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma in Adults Following Prior Vascular Endothelial Growth Factor Targeted Therapy: Clinical Trial Evidence and Experience
Therapeutic Advances in Urology
Urology
Practical Management of Adverse Events Associated With Cabozantinib Treatment in Patients With Renal-Cell Carcinoma
OncoTargets and Therapy
Oncology
Pharmacology
